Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Mylan's EpiPen According to one federal analysis, taxpayers may have overpaid for Mylan’s EpiPen by as much as $1.27 billion over 10 years as a result of its misclassification. (Photo: Shutterstock)

Senators Ron Wyden, D-Oregon, and Chuck Grassley, R-Iowa, have introduced a bill that’s aimed at the methods drug companies use to overcharge taxpayers for Medicaid rebates.

As The Hill reports, the bill, put forward by the incoming chairman and ranking member of the Senate Finance Committee, could mean that the two are looking for common ground on drug prices.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

More from this author



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO
Live Chat

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.